NAT2 antibody [N1C2]
Not tested in other applications.
|IHC (Formalin-fixed paraffin-embedded sections)||1:100-1:1000*
*Optimal dilutions/concentrations should be determined by the researcher.
|Predicted Target Size||34 kDa (note)
|Positive Controls||293T , A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji|
(Please refer to the vial label for the specific concentration)|
|Purification||Purified by antigen-affinity chromatography.|
|Full Name||N-acetyltransferase 2 (arylamine N-acetyltransferase)|
|Product Description||Rabbit Polyclonal antibody to NAT2 (N-acetyltransferase 2 (arylamine N-acetyltransferase))|
|Background||This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq]|
|Synonyms||AAC2 antibody, PNAT antibody, NAT2 antibody, arylamine N-acetyltransferase 2 antibody, NAT-2 antibody, N-acetyltransferase type 2 antibody, arylamide acetylase 2 antibody, N-acetyltransferase 2 (arylamine N-acetyltransferase) antibody|
|Cellular Localization||Cytoplasm |
|Immunogen||Recombinant protein encompassing a sequence within the center region of human NAT2. The exact sequence is proprietary.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Predict Reactivity Note||Rhesus Monkey (91%)|